Applying Decision Analysis to Inform the US Food and Drug Administration’s Benefit–Risk Assessment of Ticagrelor for Primary Prevention of Myocardial Infarction or Stroke Based on THEMIS

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2021-08, Vol.144 (8), p.655-658
Hauptverfasser:	Lackey, Leila G., Garnett, Christine E., Senatore, Fred
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse Drug Reaction Reporting Systems Cardiac & Cardiovascular Systems Cardiovascular System & Cardiology Decision Support Techniques Humans Life Sciences & Biomedicine Myocardial Infarction - prevention & control Peripheral Vascular Disease Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - therapeutic use Primary Prevention Purinergic P2Y Receptor Antagonists - administration & dosage Purinergic P2Y Receptor Antagonists - therapeutic use Risk Assessment Science & Technology Stroke - prevention & control Ticagrelor - administration & dosage Ticagrelor - therapeutic use United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!